Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Bluebird Bio Ord Shs (NQ: BLUE)
63.84 USD  +1.78 (+2.87%)
Official Closing Price  /  Updated: 4:49 PM EDT, Aug 6, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 1,545,579
Open 63.20
Bid (Size) 64.00 (10)
Ask (Size) 64.84 (1)
Prev. Close 62.06
Today's Range 62.87 - 68.39
52wk Range 38.95 - 126.39
Shares Outstanding 50,119,272
Dividend Yield N/A
Performance
YTD
-26.09%
-26.09%
1 Month
+9.92%
+9.92%
3 Month
+16.39%
+16.39%
6 Month
-30.53%
-30.53%
1 Year
-47.26%
-47.26%
Top News
More News
Advancing Early-detection Measures Seek to Curb Cancer's Progression
FinancialBuzz.com News Commentary Read More
from PR Newswire
bluebird bio Reports Second Quarter 2020 Financial Results and Recent Operational Progress
bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the second quarter ended June 30, 2020 and shared recent operational progress. Read More
from Business Wire News Releases
More News
Read More
bluebird bio Announces August Investor Event
from Business Wire News Releases
Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple My
from Business Wire News Releases
Why Bluebird Bio's Stock Is Trading Higher Today
category BLUE , Market News , Earnings , and 3 more.
from Benzinga
New Data Show Near Elimination of Sickle Cell Disease-Related Vaso-Occlusive Crises and Acute Chest Syndrome in Phase 1/2 Clinical Study of bluebird bio’s LentiGlobin™ Gene Therapy for Sickle Cell Dis
from Business Wire News Releases
Majority of Evaluable Patients Across Genotypes Achieve Transfusion Independence and Maintain It with Near-Normal Hemoglobin Levels in Phase 3 Studies of betibeglogene autotemcel (LentiGlobin™ for β-t
from Business Wire News Releases
Tuesday's ETF Movers: XBI, KBWB
category ETFs
from ETF Channel
Is Intellia Therapeutics Stock a Buy?
category NTLA , Market News , CRSP , and 3 more.
from Motley Fool
First Week of February 2021 Options Trading For bluebird bio (BLUE)
category Stocks
from Market News Video
Biotech Stocks Rise After FDA Halts Test By Rival Blood Cancer Firm Cellectis
from Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.